<?xml version="1.0" encoding="utf-8"?>  
		   <iati-activities version="2.03" generated-datetime="2026-10-15T13:29:24">
		   <iati-activity last-updated-datetime="2026-10-15T13:29:24"
		   xml:lang="EN" default-currency="USD" hierarchy="01">
		   <iati-identifier>XI-IATI-WBTF-TF071457</iati-identifier>
		   <reporting-org ref="XI-IATI-WBTF" type="40">  
		   		   <narrative>World Bank Trust Funds</narrative>
		   </reporting-org>
		   <title>
		   <narrative>Support to International AIDS Vaccine Initiative Trust Fund (Formerly known as IAVISendai Vector)	   </narrative>
		   </title>
		   <description type="1">
		   <narrative>The objective of this trust fund is to develop a new candidate HIV  vaccine. The grant will support the International AIDS Vaccine  Initiative (IAVI) in the development and trial of a novel vaccine  candidate - the Sendai Vector, with a work program of 5 years and a  requested budget of $10M.  The prevention of HIV infection by an  effective vaccine remains the single intervention that has feasible  potential to reverse and eradicate the global AIDS epidemic, with  profound implications for the development of affected countries and  populations. This grant supports IAVI in the search for a preventative  HIV vaccine as a Global Public Good through a program of fundamental  laboratory, epidemiological and clinical research, outlined in the  project proposal. </narrative>
		   </description><participating-org ref="TF513001" type="10" role="1" >
       <narrative>Japan - Ministry of Finance </narrative>
       </participating-org><participating-org ref="XI-IATI-WBTF" type="40" role="4" >
       <narrative>World Bank Trust Funds </narrative>
       </participating-org> <activity-status code="3"></activity-status><activity-date type="1"  iso-date= "2010-06-24"></activity-date><activity-date type="2"  iso-date= "2010-06-24"></activity-date><activity-date type="3"  iso-date= "2017-12-31"></activity-date><activity-date type="4"  iso-date= "2018-05-30"></activity-date> <contact-info type="3">
       <organisation>
       <narrative></narrative>
       </organisation>
       <department>
       <narrative>HIS-Off. of VP &amp; Head of Network</narrative>
       </department>
       <person-name>
       <narrative></narrative>
       </person-name>
       <job-title>
       <narrative></narrative>
       </job-title>
       <telephone>1202-458-7916</telephone>
       <email></email>
       <mailing-address>
       <narrative>1818 H St, NW, Washington DC - 22036</narrative>
       </mailing-address>
       </contact-info><activity-scope code="1"></activity-scope> <recipient-region code="998">   <narrative>Bilateral unspecified</narrative>
       </recipient-region> <sector code="13040" 
	    vocabulary="1" percentage="100.00">
       <narrative>+![cdata[STD control including HIV/AIDS]]+</narrative>
       </sector><collaboration-type code="2"></collaboration-type>
       <default-aid-type code="B03"></default-aid-type>
       <default-tied-status code="5"></default-tied-status><budget type="1">
       <period-start iso-date="2010-06-24"></period-start> 
       <period-end iso-date="2017-12-31"> </period-end>
       <value currency="USD" value-date="2026-03-31">10000000.00 </value>
       </budget><transaction>
	  <transaction-type code="1"></transaction-type>
       <transaction-date iso-date="2020-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">10000000.00  </value>
		   <description>
       <narrative>Incoming Funds (Cumulative Paid-In Contribution )-as of June 30th, 2020</narrative> 
       </description> 
	    <provider-org provider-activity-id="TF513001">
       <narrative>Japan - Ministry of Finance</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-TF071457">
       <narrative>Support to International AIDS Vaccine Initiative Trust Fund (Formerly known as IAVISendai Vector)</narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="11"></transaction-type>
       <transaction-date iso-date="2020-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">10000000.00  </value>
		   <description>
       <narrative>Incoming Commitment(Cumulative Signed Contribution)-as of June 30th, 2020</narrative> 
       </description> 
	    <provider-org provider-activity-id="TF513001">
       <narrative>Japan - Ministry of Finance</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-TF071457">
       <narrative>Support to International AIDS Vaccine Initiative Trust Fund (Formerly known as IAVISendai Vector)</narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="2"></transaction-type>
       <transaction-date iso-date="2020-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">513356.44  </value>
		   <description>
       <narrative>Allocation to Bank executed activities - as of June 30th, 2020</narrative> 
       </description> 
	    <provider-org provider-activity-id="XI-IATI-WBTF-TF071457">
       <narrative>Support to International AIDS Vaccine Initiative Trust Fund (Formerly known as IAVISendai Vector)</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P119051">
       <narrative>Bilateral, unspecified</narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="2"></transaction-type>
       <transaction-date iso-date="2020-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">835.55  </value>
		   <description>
       <narrative>Allocation to Bank executed activities - as of June 30th, 2020</narrative> 
       </description> 
	    <provider-org provider-activity-id="XI-IATI-WBTF-TF071457">
       <narrative>Support to International AIDS Vaccine Initiative Trust Fund (Formerly known as IAVISendai Vector)</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-">
       <narrative></narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="2"></transaction-type>
       <transaction-date iso-date="2020-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">9260256.00  </value>
		   <description>
       <narrative>Outgoing Commitment ( Total Grant Allocated Amount to Project ) - as of June 30th, 2020</narrative> 
       </description> 
	    <provider-org provider-activity-id="XI-IATI-WBTF-TF071457">
       <narrative>Support to International AIDS Vaccine Initiative Trust Fund (Formerly known as IAVISendai Vector)</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P119051">
       <narrative>Bilateral, unspecified</narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><related-activity ref="XI-IATI-WBTF-P119051"  type="2"></related-activity>
   </iati-activity>	<iati-activity last-updated-datetime="2026-10-15T13:29:26"
	   xml:lang="EN" default-currency="USD" hierarchy="02">
       <iati-identifier>XI-IATI-WBTF-P119051</iati-identifier>
       <reporting-org ref="XI-IATI-WBTF"  type="40">
       <narrative>World Bank Trust Funds</narrative>
       </reporting-org>
       <title>
       <narrative>Support to IAVI-Sendai Vector</narrative>
       </title>
       <description type="1">
       <narrative>&quot; &lt;span style=&quot;&quot;font-family:times new roman,serif; font-size:12pt&quot;&quot;&gt;The objective of this trust fund is to develop a new candidate HIV vaccine. The grant will support the International AIDS Vaccine Initiative (IAVI) in the development and trial of a novel vaccine candidate - the Sendai Vector, with a work program of 5 years and a requested budget of $10M. The prevention of HIV infection by an effective vaccine remains the single intervention that has feasible potential to reverse and eradicate the global AIDS epidemic, with profound implications for the development of affected countries and populations. This grant supports IAVI in the search for a preventative HIV vaccine as a Global Public Good through a program of fundamental laboratory, epidemiological and clinical research.&lt;/span&gt;  &quot; </narrative>
	   </description><participating-org ref="TF071457" type="40" role="4" >
       <narrative>Support to International AIDS Vaccine Initiative Trust Fund (Formerly known as IAVI-Sendai Vector) </narrative>
       </participating-org><participating-org ref="TF513001" type="10" role="1" >
       <narrative>Japan - Ministry of Finance </narrative>
       </participating-org> <activity-status code="3"></activity-status><activity-date type="1"  iso-date= "2010-07-01"></activity-date><activity-date type="2"  iso-date= "2010-07-01"></activity-date><activity-date type="3"  iso-date= "2017-12-31"></activity-date><activity-date type="4"  iso-date= "2018-01-22"></activity-date> <contact-info type="2">
       <organisation>
       <narrative></narrative>
       </organisation>
       <department>
       <narrative></narrative>
       </department>
       <person-name>
       <narrative>Mr Robert Oelrichs</narrative>
       </person-name>
       <job-title>
       <narrative>Short Term Consultant</narrative>
       </job-title>
       <telephone>1202-458-7916</telephone>
       <email></email>
       <mailing-address>
       <narrative>1818 H St, NW, Washington DC - 22036</narrative>
       </mailing-address>
       </contact-info><activity-scope code="1"></activity-scope> <recipient-region code="998">   <narrative>Bilateral unspecified</narrative>
       </recipient-region> <sector code="13040"  vocabulary="1" percentage="100.00">
       <narrative>+![cdata[STD control including HIV/AIDS]]+</narrative>
       </sector><collaboration-type code="2"></collaboration-type>
       <default-aid-type code="C01"></default-aid-type>
       <default-tied-status code="5"></default-tied-status><budget type="1">
       <period-start iso-date="2010-07-01"></period-start> 
       <period-end iso-date="2017-12-31"> </period-end>
       <value currency="USD" value-date="2026-03-31">9773612.44 </value>
       </budget><transaction>
	  <transaction-type code="11"></transaction-type>
       <transaction-date iso-date="2020-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">513356.44  </value>
		   <description>
       <narrative>Allocation to Bank executed activities - as of June 30th, 2020</narrative> 
       </description> 
	    <provider-org provider-activity-id="XI-IATI-WBTF-TF071457">
       <narrative>Support to International AIDS Vaccine Initiative Trust Fund (Formerly known as IAVI-Sendai Vector)</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="P119051">
       <narrative>Bilateral, unspecified</narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="11"></transaction-type>
       <transaction-date iso-date="2020-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">9260256.00  </value>
		   <description>
       <narrative>Incoming Commitment (Total Grant Allocated Amount) - as of June 30th, 2020</narrative> 
       </description> 
	    <provider-org provider-activity-id="XI-IATI-WBTF-TF071457">
       <narrative>Support to International AIDS Vaccine Initiative Trust Fund (Formerly known as IAVI-Sendai Vector)</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="P119051">
       <narrative>Bilateral, unspecified</narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="3"></transaction-type>
       <transaction-date iso-date="2020-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">9260256.00  </value>
		   <description>
       <narrative>Disbursement(Total Recipient-Executed Trust Funds Disbursements ) - as of June 30th, 2020</narrative> 
       </description>
	    <provider-org provider-activity-id="XI-IATI-WBTF">
       <narrative>World Bank Trust Funds</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P119051">
       <narrative></narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="4"></transaction-type>
       <transaction-date iso-date="2020-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">514191.99  </value>
		   <description>
       <narrative>Cumulative Expenditures to Bank executed activities - as of June 30th, 2020</narrative> 
       </description>
	    <provider-org provider-activity-id="XI-IATI-WBTF">
       <narrative>World Bank Trust Funds</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P119051">
       <narrative></narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><related-activity ref="XI-IATI-WBTF-TF071457" type="1"></related-activity><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
Have conducted animal studies to determine the immunogenicity of Sev-EnvF compared to another candidate
</narrative></title> 
<baseline year="2015" iso-date="2015-01-05" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2015-01-05" />  <period-end iso-date="2015-12-30" />
<target value="Performed">


																	</target>

																	<actual value="Performed">


																	</actual>

																	</period>
</indicator>
</result><result type="2" aggregation-status="0">
<title><narrative>
 PDO Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
Production of a novel candidate HIV vaccine based on the Sendai vector
</narrative></title> 
<baseline year="2010" iso-date="2010-09-15" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2010-09-15" />  <period-end iso-date="2015-06-30" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
To have completed a 1-year follow-up post last vaccination in the study and consolidated immunogenicity data
</narrative></title> 
<baseline year="2010" iso-date="2010-09-15" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2010-09-15" />  <period-end iso-date="2015-06-30" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
To have completed all vaccinations (administration at 0, 4 months) and generated consolidated safety and preliminary immunogenicitydata
</narrative></title> 
<baseline year="2010" iso-date="2010-09-15" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2010-09-15" />  <period-end iso-date="2014-06-30" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
To have completed enrollment of Groups B, C and DE and generated preliminary safety data
</narrative></title> 
<baseline year="2010" iso-date="2010-09-15" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2010-09-15" />  <period-end iso-date="2013-12-31" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
To have completed Group A Administration
</narrative></title> 
<baseline year="2010" iso-date="2010-09-15" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2010-09-15" />  <period-end iso-date="2013-12-31" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
SeV-Gag vector clinical trial material released
</narrative></title> 
<baseline year="2010" iso-date="2010-09-15" value="Yes"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2010-09-15" />  <period-end iso-date="2011-12-31" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
Have conducted immunogenicity studies in suitable animal model demonstrating that SeV-HIV-Immunogens vaccine candidate elicits immune response to HIV when administered at safe dose ranges.
</narrative></title> 
<baseline year="2010" iso-date="2010-09-15" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2010-09-15" />  <period-end iso-date="2012-09-30" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
Have conducted immunogenicity studies in suitable animal model demonstrating that SeV-Gag vaccine elicits immune response to HIV when administered at safe dose ranges
</narrative></title> 
<baseline year="2010" iso-date="2010-09-15" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2010-09-15" />  <period-end iso-date="2011-03-30" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
Have conducted virulence studies in suitable animal model with SeV-Gag.
</narrative></title> 
<baseline year="2010" iso-date="2010-09-15" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2010-09-15" />  <period-end iso-date="2011-06-30" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
In parallel, have constructed vaccine candidate using SeV as vector that express the additional  HIV  immunogens  appropriately andhave completed Genetic Stability assessment.
</narrative></title> 
<baseline year="2010" iso-date="2010-09-15" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2010-09-15" />  <period-end iso-date="2012-03-30" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
Have achieved genetic stability evaluation of the SeV-Gag vaccine candidate.
</narrative></title> 
<baseline year="2010" iso-date="2010-09-15" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2010-09-15" />  <period-end iso-date="2010-12-31" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
Have constructed vaccine candidate using SeV as vector that express the HIV Gag appropriately
</narrative></title> 
<baseline year="2010" iso-date="2010-09-15" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2010-09-15" />  <period-end iso-date="2010-06-30" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
SeV-Gag vector GMP material for toxicity studies released
</narrative></title> 
<baseline year="2010" iso-date="2010-09-15" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2010-09-15" />  <period-end iso-date="2011-09-30" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
Process developed to support SeV-Gag vaccine candidate manufacturing at clinical trial scale.
</narrative></title> 
<baseline year="2010" iso-date="2010-09-15" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2010-09-15" />  <period-end iso-date="2011-06-30" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
Have prepared and submitted clinical trial application to regulatory, ethics and biosafety committees  for SeV-Gag vaccine candidate as required.
</narrative></title> 
<baseline year="2010" iso-date="2010-09-15" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2010-09-15" />  <period-end iso-date="2012-09-30" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
To have completed enrollment of Groups A, generated preliminary safety data and obtained approval from independent Safety Review Board
</narrative></title> 
<baseline year="2010" iso-date="2010-09-15" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2010-09-15" />  <period-end iso-date="2013-09-13" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
To have initiated a Phase I dose-escalation, safety and immunogenicity trial with SeV-Gag and Ad35-HIV in prime-boost regimens.
</narrative></title> 
<baseline year="2010" iso-date="2010-09-15" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2010-09-15" />  <period-end iso-date="2013-06-30" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
Have conducted toxicity in selected animal model with SeV-Gag vaccine candidate to establish safe starting dose for clinical trialsand no significant toxicology findings
</narrative></title> 
<baseline year="2010" iso-date="2010-09-15" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2010-09-15" />  <period-end iso-date="2012-06-30" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result></iati-activity></iati-activities>